Xiaoyu Sun

Dr. Xiaoyu Sun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Antiviral Research
Verified
Journal Article
Closed access
XSXiaoyu Sun
Xiaoyu Sun
HMHanwen Ma
Hanwen Ma
XWXuanjia Wang
Xuanjia Wang
ZBZhiheng Bao
Zhiheng Bao
STShubing Tang
Shubing Tang
BSBing Sun
Bing Sun

28 April 2025 in OncoImmunology
Verified
Journal Article
Open access
RWRan Wang
Ran Wang
JXJiefang Xu
Jiefang Xu
SCShipeng Cheng
Shipeng Cheng
ZLZhiyang Ling
Zhiyang Ling
WSWangmo Sonam
Wangmo Sonam
BSBing Sun
Bing Sun
Modulation or depletion of tumor-infiltrating Tregs (Ti-Tregs) is a promising strategy in the field of antitumor immunotherapy. However, this approach poses challenges due to the diversity within the Treg population and the lack of precision in targeting Ti-Tregs. To selectively and efficiently eliminate Ti-Tregs while sparing other immune cells, we developed a bispecific antibody, FT10-Fab, targeting TNFR2 and CCR8, which are highly expressed on Ti-Tregs. Our results showed that FT10-Fab outperformed the monotherapies in several tumor models by significantly reducing the proportion of Ti-Tregs while increasing the proportion of CD8+ T cells. FT10-Fab was able to target and eliminate Ti-Tregs expressing TNFR2 or CCR8 (TNFR2+or CCR8+ Tregs), particularly TNFR2+ CCR8+ Tregs, which are the most important proliferative and protumorigenic Tregs. In addition, FT10-Fab relies on CD8+ T cells for its antitumor function and induces robust immune memory. Furthermore, the combination of FT10-Fab with PD-1 blockade showed synergistic therapeutic efficacy against tumors by significantly suppressing Tregs and enhancing effector CD8+ T cell function. Taken together, our findings suggest that precision depletion of Ti-Tregs via the bispecific TNFR2/CCR8 antibody is a potential therapeutic for cancer immunotherapy, while combination with anti-PD1 amplifies the antitumor effect.

4 June 2025 in iScience
Verified
Journal Article
Open access
JXJiefang Xu
Jiefang Xu
RWRan Wang
Ran Wang
SCShipeng Cheng
Shipeng Cheng
SWSonam Wangmo
Sonam Wangmo
JYJichao Yang
Jichao Yang
BSBing Sun
Bing Sun
Immune checkpoint therapy has transformed cancer treatment, yet efficacy and safety challenges persist. Selectively inhibiting tumor-infiltrating regulatory T cells (Ti-Tregs) while enhancing CD8+ T cell function are complementary strategies in cancer immunotherapy. Here, we engineered a bispecific antibody, FRP303, targeting 4-1BB and CCR8, which are co-expressed on a highly immunosuppressive subset of Ti-Tregs. In vivo, FRP303 outperformed monoclonal antibodies in CT26 and MC38 colorectal tumors and poorly immunogenic B16F10 melanoma. Treatment with FRP303 reduced Ti-Treg frequency, increased CD8+ T cell infiltration, and elevated antitumor cytokines IFN-γ and TNF-α. Safety assessments showed FRP303 does not disrupt immune homeostasis in peripheral tissues or induce significant hepatotoxicity. Moreover, FRP303 demonstrated strong synergistic effects when combined with a PD-1 antibody. In summary, FRP303 mediated anti-tumor activity through a dual mechanism involving the selective depletion of Ti-Tregs and the enhancement of CD8+ T cell function, offering a promising strategy for cancer immunotherapy.

25 June 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
XLXiao Lu
Xiao Lu
ZCZiyue Chen
Ziyue Chen
CYChunyan Yi
Chunyan Yi
ZLZhiyang Ling
Zhiyang Ling
JYJing Ye
Jing Ye
BSBing Sun
Bing Sun
Cluster of differentiation 47 (CD47) is a widely expressed transmembrane protein that plays a crucial role in immune self-recognition. Cancer cells upregulate CD47 expression to promote immune escape through activating the "don't eat me" signal via interactions with signal regulatory protein α (SIRPα) on macrophages. The effectiveness of anti-CD47 antibodies has been demonstrated in multiple tumor models. However, since CD47 is also expressed in human red blood cells (RBCs) and platelets, the clinical application of anti-CD47 antibodies requires careful consideration of blood toxicity. One major obstacle to the clinical application of CD47 antibodies is the hemagglutination caused by RBCs cross-linking. In this study, we generated Hu1C8, a humanized anti-CD47 monoclonal antibody that demonstrated increased selectivity for binding to CD47 on cancer cells and lacked hemagglutination activity. Epitope mapping and the crystal structure of the Hu1C8 Fab-CD47 extracellular domain (ECD) complex revealed that Hu1C8 binds to a distinct epitope of CD47 in a Ca2+-dependent manner. The unique recognition and binding mode allowed Hu1C8 to bind CD47 on RBCs with reduced hemagglutination activity while still maintaining effective antitumor activity. These findings demonstrate a feasible strategy for developing CD47 antibodies with high antitumor activity but low RBC hemagglutination activity. Our study elucidates how epitope-specific antibody influences antibody-induced cell cross-linking, offering innovative strategies for antibody design to either leverage or avoid cell cross-linking effects.

3 December 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
ZLZhiyang Ling
Zhiyang Ling
ZZZhangqian Zheng
Zhangqian Zheng
LXLingli Xu
Lingli Xu
CYChunyan Yi
Chunyan Yi
XDXinran Dong
Xinran Dong
Wenhao ZhouWenhao Zhou
Wenhao Zhou